Intensity Therapeutics Inc. (INTS)
INTS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | INTS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001567264 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, the Company believes there is substantial doubt about its ability to continue as a going concern." | 10-Q 2026-11-05 |
| Cash and burn | $8.5M cash; operating cash flow -$2.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 3,301,175 (2026-11-04); 60,064,965 a year earlier; 13,709,377 three years earlier. 1y figure adjusted for split (1-for-25 overall); 3y figure adjusted for split (1-for-25 overall). | Cover page 2026-11-04 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2026-02-19 | Source 2026-02-19 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-03-23 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2025-12-05 |
| Auditor | EisnerAmper LLP, New York, New York, United States | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$3.5M | -$2.5M | $8.5M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$3.0M | -$2.3M | $9.5M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2026 2026-03-31 | Not filed | -$2.4M | -$1.8M | $10.2M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-12-31 | Not filed | -$3.1M | -$2.4M | $11.9M | No debt tags | Needs four quarters | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | Not filed | -$2.7M | -$2.4M | $7.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$2.5M | -$2.5M | $2.2M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q1 2025 2025-03-31 | Not filed | -$3.3M | -$2.0M | $929K | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2024 2024-12-31 | Not filed | -$3.2M | -$2.7M | $2.6M | No debt tags | Needs four quarters | 10-K 2026-03-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-23 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 246 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.7% |
| 1 month | -13.2% |
| 3 months | -23.0% |
| Year to date | -70.0% |
| 1 year | -74.2% |
| From 52-week high | -79.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALGS | Aligos Therapeutics Inc. | $1.66 | -20.95% | $10.4M |
| SCLX | Scilex Holding Company | $1.25 | -12.59% | $10.6M |
| TCRX | TScan Therapeutics Inc. | $0.1451 | -9.65% | $9.2M |
| INAB | IN8bio Inc. | $0.8160 | -0.49% | $8.8M |
| BCDA | BioCardia Inc. | $0.7901 | -4.92% | $12.0M |
| DYAI | Dyadic International Inc. | $0.3200 | -2.14% | $12.8M |
| JSPR | Jasper Therapeutics Inc. | $11.77 | -13.96% | $13.1M |
| PASG | Passage Bio Inc. | $4.13 | -2.82% | $13.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier